Trials / Active Not Recruiting
Active Not RecruitingNCT06813222
Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Damanhour University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Anemia-Related Outcomes in Patients with CKD Treated with Dapagliflozin This study aims to identify factors that predict anemia improvement in chronic kidney disease (CKD) patients using Dapagliflozin, an SGLT2 inhibitor. Key questions: * What factors influence how well Dapagliflozin improves anemia in CKD patients? * Are there specific characteristics that predict better responses to Dapagliflozin treatment? The investigators will review medical records of CKD patients who started taking Dapagliflozin. The investigators will compare those with low hemoglobin levels (anemia) to those without anemia. The investigators will analyze: Changes in hemoglobin levels Other factors related to anemia (e.g., iron levels, TIBC, ferritin) Patient characteristics (e.g., age, sex, CKD stage) This study will help us understand which CKD patients are most likely to benefit from Dapagliflozin for anemia.
Detailed description
Study Title: Anemia-Related Outcomes in Patients with CKD Treated with Dapagliflozin Purpose: This prospective observational study aims to investigate factors associated with anemia improvement in CKD patients treated with Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The study will analyze data from medical records to identify predictors of favorable anemia outcomes in this population. Study Design: A prospective cohort study will be conducted using medical records from the Kidney and Urology Center in Alexandria, Egypt. Patients with CKD who initiated Dapagliflozin therapy will be included, and their clinical data will be analyzed to assess the impact of Dapagliflozin on anemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin (DAPA) | Dapagliflozin 10 mg |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2025-03-01
- Completion
- 2025-03-01
- First posted
- 2025-02-06
- Last updated
- 2025-02-06
Locations
1 site across 1 country: Egypt
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06813222. Inclusion in this directory is not an endorsement.